How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Neoantigen Targeted Therapies Market
- By Therapy Type: Neoantigen-based Cancer Vaccines, Neoantigen-specific T-cell Therapy, Neoantigen-targeted Immune Checkpoint Inhibitors, Neoantigen-directed Monoclonal Antibodies
- By Cancer Indication: Non-Small Cell Lung Cancer (NSCLC), Melanoma, Colorectal Cancer, Ovarian Cancer, Glioblastoma
- By Technology Platform: Next-Generation Sequencing (NGS), Bioinformatics and AI-driven Neoantigen Prediction, Synthetic Peptide Synthesis, mRNA-based Neoantigen Delivery
- By End User: Hospitals and Cancer Treatment Centers, Research Institutes, Contract Research Organizations (CROs), Biopharmaceutical Companies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Neoantigen-based Cancer Vaccines leads By Therapy Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 18 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 282 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.164 →
- 11 Company Profiles 18 players: SWOT & benchmarking p.172 →
Full report · locked preview
Everything inside the Neoantigen Targeted Therapies Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 18 company profiles, forecast to 2033.
Segmentation covered
Therapy Type 4
Cancer Indication 5
Technology Platform 4
End User 4
Companies profiled
Moderna Inc.
BioNTech SE
Gritstone Oncology Inc.
Neon Therapeutics
Inc. (acquired by BioNTech)
Immunocore Limited
Genocea Biosciences Inc.
Adaptimmune Therapeutics plc
Immatics Biotechnologies GmbH
Kite Pharma
Inc. (a Gilead Company)
Genentech
+6 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
18 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Moderna Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →BioNTech SE
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Gritstone Oncology Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Neon Therapeutics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Inc. (acquired by BioNTech)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Immunocore Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Genocea Biosciences Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Adaptimmune Therapeutics plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Immatics Biotechnologies GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Kite Pharma
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Inc. (a Gilead Company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Genentech
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Inc. (a member of the Roche Group)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Agenus Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.232 →Neon Therapeutics (now part of BioNTech)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →CureVac N.V.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Eureka Therapeutics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Tmunity Therapeutics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.256 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,727M by 2033 · 10.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Neoantigen-based Cancer Vaccines62.7
- Neoantigen-specific T-cell Therapy9.1
- Neoantigen-targeted Immune Checkpoint Inhibitors19.1
- Neoantigen-directed Monoclonal Antibodies9.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$714.5M → $1,614M · 10.7%
Europe$498.0M → $1,082M · 10.2%
Asia Pacific$454.7M → $1,065M · 11.2%
Latin America$281.5M → $654.7M · 11.1%
Middle East and Africa$216.5M → $467.1M · 10.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.202026
10.222027
10.222028
10.242029
10.242030
10.262031
10.272032
10.282033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Moderna Inc.16.7
- BioNTech SE12.4
- Gritstone Oncology Inc.13.4
- Neon Therapeutics6.4
- Inc. (acquired by BioNTech)11.0
- Immunocore Limited12.1
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapy Type24.8%
Cancer Indication33.6%
Technology Platform15.0%
End User26.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.1
- Europe22.2
- Asia Pacific21.8
- Latin America13.4
- Middle East and Africa9.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Moderna Inc. | 95 | 96 | 91 | 78 | 86 | 84 | 88 |
| BioNTech SE | 89 | 81 | 71 | 91 | 89 | 75 | 83 |
| Gritstone Oncology Inc. | 79 | 88 | 88 | 82 | 72 | 65 | 79 |
| Neon Therapeutics | 69 | 67 | 73 | 61 | 66 | 58 | 66 |
| Inc. (acquired by BioNTech) | 58 | 52 | 71 | 57 | 76 | 67 | 64 |
| Immunocore Limited | 63 | 69 | 59 | 48 | 60 | 61 | 60 |
| Genocea Biosciences Inc. | 64 | 57 | 43 | 41 | 61 | 42 | 51 |
| Adaptimmune Therapeutics plc | 54 | 38 | 60 | 58 | 43 | 53 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Moderna Inc.
- BioNTech SE
- Gritstone Oncology Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Moderna Inc. | ✓ | ✓ | ✓ | ✓ | ◐ | ✓ |
| BioNTech SE | ✓ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Gritstone Oncology Inc. | ◐ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Neon Therapeutics | ◐ | ◐ | ◐ | − | ◐ | − |
| Inc. (acquired by BioNTech) | ◐ | − | ◐ | ◐ | ◐ | ◐ |
| Immunocore Limited | ◐ | ✓ | ◐ | ◐ | − | ◐ |
| Genocea Biosciences Inc. | ◐ | ◐ | − | − | − | − |
| Adaptimmune Therapeutics plc | ◐ | − | − | ◐ | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Moderna Inc.88
2BioNTech SE83
3Gritstone Oncology Inc.79
4Neon Therapeutics66
5Inc. (acquired by BioNTech)64
6Immunocore Limited60
7Genocea Biosciences Inc.51
8Adaptimmune Therapeutics plc51
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Moderna Inc.BioNTech SEGritstone Oncology Inc.
Contender3
Focused players with pockets of strength.
Neon TherapeuticsInc. (acquired by BioNTech)Immunocore Limited
Niche2
Specialists in a single segment or region.
Genocea Biosciences Inc.Adaptimmune Therapeutics plc
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapy Type in North America, then scale across Neoantigen Targeted Therapies Market — a $473M beachhead inside a $6.91B market.
Beachhead (SOM)$473Mobtainable near-term
Serviceable (SAM)$2.88Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Neoantigen-based Cancer Vaccines
Best fit — highest urgency & budget in Therapy Type.
Economic buyer78 fit
Neoantigen-specific T-cell Therapy
Strong fit — clear ROI and a fast path to value.
End user66 fit
Neoantigen-targeted Immune Checkpoint Inhibitors
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapy Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Cancer Indication & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Technology Platform
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel27%
Digital / self-serve23%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Therapy Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Neoantigen Targeted Therapies Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified21%
Evaluation11%
Closed-won6%
$17.0KCAC
$98KLTV
5.8:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Neoantigen Targeted Therapies Market is a high-growth opportunity — $4.12B by 2033, compounding at 10.6%.
TAM · 2025$1.84Btoday
TAM · 2033$4.12Bforecast
CAGR10.6%2027–2033
Cumulative$25.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.12BTotal addressable market
SAM$1.64BServiceable available market
SOM$356MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.6% CAGR
Demand compounds through 2033, outpacing GDP across Therapy Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapy Type moving from early to mainstream — durable secular demand.
Consolidation upside
18+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.12BLarge & growingTAM by 2033 at 10.6% CAGR
$1.64BServiceable nowreachable with today’s model
$356MBeachhead winobtainable near-term share
18+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.22BBear6.9% CAGR
$4.12BBase10.6% CAGR
$5.28BBull14.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Cancer Indication optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Neoantigen Targeted Therapies Market — a $4.32B market by 2033. Plan: grow share from 9.7% to 17.9%.
Market size · 2033$4.32Btotal addressable
Market CAGR4.7%2027–2033
Target share17.9%from 9.7% today
Revenue ambition$773Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.7% | 17.9% | On track |
| Revenue | $417M | $773M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 33.8% | 38.6% | Ahead |
| Customer retention | 90.4% | 94.8% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapy Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Cancer Indication capability
A defensible second engine — invest in Cancer Indication to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapy Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Cancer Indication
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $79M capacity & capability investment
- Greenlight bolt-on M&A in Cancer Indication
- Authorise North America expansion plan
- Fund R&D program for Therapy Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAhead
- Input-cost & supply riskAt risk
- Regulatory / policy changeBehind
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Neoantigen Targeted Therapies Market conversation — a $9.75B market you can size, segment and defend in minutes.
Market size · 2033$9.75Btotal opportunity
Growth9.2%CAGR to 2033
Addressable buyers1,498+accounts in scope
Typical ROI6.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapy Type
Goal Grow share in Therapy Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.5×return on cost, year one
< 3 mopayback period
$61K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
18+players profiled in this market
Coverage includes
Moderna Inc.BioNTech SEGritstone Oncology Inc.Neon TherapeuticsInc. (acquired by BioNTech)Immunocore LimitedGenocea Biosciences Inc.Adaptimmune Therapeutics plc+10 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Neoantigen Targeted Therapies Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Neoantigen Targeted Therapies Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Needlestick Safety Injection Devices Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportNeedle Free Injectior Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportNeedle Counters Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportNebulizing Masks Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportNebulization Masks Market
Market size, share, segmentation and regional forecast.
$386M market · 2025 base year
View reportMultipurpose Drainage Catheter Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportMultiple-use Bioreactors Market
Market size, share, segmentation and regional forecast.
$443M market · 2025 base year
View reportChlorhexidine Gluconate (CHG) Cloth Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportCentral Vascular Access Devices Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportMultimodality Radiation Shielding Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportMultimodal Imaging Systems Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportCardiovascular CT System Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.